Medicine Recommendations

Type 1 and type 2 diabetes mellitus

Type 1 and type 2 diabetes mellitus

Treatment of diabetes mellitus in adults

Diabetes monitoring

Reason for decision: A specialist clinician or the clinician who oversees the patient’s diabetes care still needs to determine a patient’s eligibility. When a patient satisfies the eligibility criteria, ongoing supplies of sensors can now be prescribed by GPs. The initiating clinician must have received appropriate training on the initiation and use of flash glucose monitoring products and will supply the patient with a scanning device and sensors to cover the initial 2 weeks of use of flash glucose monitoring.

Hypothyroidism

Treatment of Acid Reflux and Dysphagia

Depressive illness

Type 1 and type 2 diabetes mellitus

Acne

MHRA Drug Safety Update - Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders

MHRA Drug Safety Update - Oral retinoids: pregnancy prevention—reminder of measures to minimise teratogenic risk

MHRA Drug Safety Update - Isotretinoin: risk of serious skin reactions

MHRA Drug Safety Update - Isotretinoin for severe acne: who should prescribe it

MHRA Drug Safety Update - Isotretinoin: new safety measures to be introduced in the coming months, including additional oversight on initiation of treatment for patients under 18 years

Constipation in adults

Heart failure (NICE TA267), and chronic angina

NICE TA267 - Ivabradine for treating chronic heart failure 

MHRA Drug Safety Update - Ivabradine and the risk of cardiac side effects

MHRA Drug Safety Update - Ivabradine: carefully monitor for bradycardia

Topical treatment of inflammatory lesions of rosacea (papulopustular) in adults

Ixekizumab for treating moderate to severe plaque psoriasis (NICE TA442)

NICE TA442 - Ixekizumab for treating moderate to severe plaque psoriasis

Treatment of active psoriatic arthritis in adults after inadequate response to DMARDs

NICE TA537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs

Treating axial spondyloarthritis.

NICE TA718 - Ixekizumab for treating axial spondyloarthritis

Chronic Non-Cancer Pain (off-label use) in adults

 Chronic Non-Cancer Pain (off-label use) in adults

Patients on haemodialysis

Epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Constipation